---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-029636"
form_type: "8-K"
ticker: "BFRG"
cik: "0001829247"
company_name: "BullFrog AI Holdings, Inc."
filed_at: "2025-12-30T23:59:59+00:00"
generated_at: "2026-05-16T12:01:06.130007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# BullFrog AI details 2025 progress, pharma partnerships, and 2026 catalysts

## Summary
- Annual cash burn ~$6.2M; $10M equity line and ATM provide financing flexibility.
- Multiple advanced pharma discussions for out-licensing or discovery collaborations with upfront/milestone payments.
- Sygnature Discovery collaboration expected to generate revenue through 2028; sales kickoff in Sept 2025.
- Eleison data from late-stage oncology collaboration accepted for ASCO GI Cancers Symposium Jan 9, 2026.
- Launched bfPREP data prep tool; reduces data prep from months to days, enabling earlier engagement.

## SEC filing metadata
- accession: 0001493152-25-029636
- form_type: 8-K
- ticker: BFRG
- cik: 0001829247
- company_name: BullFrog AI Holdings, Inc.
- filed_at: 2025-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829247/000149315225029636/0001493152-25-029636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829247/000149315225029636/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-029636
- JSON: https://secwatch.observer/filing/0001493152-25-029636.json
- Plain text: https://secwatch.observer/filing/0001493152-25-029636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.